eprintid: 1549825 rev_number: 27 eprint_status: archive userid: 608 dir: disk0/01/54/98/25 datestamp: 2017-05-03 17:43:30 lastmod: 2021-10-09 22:50:24 status_changed: 2017-05-03 17:43:30 type: article metadata_visibility: show creators_name: Larsson, M creators_name: Huang, W-T creators_name: Liu, D-M creators_name: Losic, D title: Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential ispublished: pub divisions: UCL divisions: B04 divisions: C05 keywords: Combinatory treatment, Drug delivery system, RNA, Synergy, Therapeutic substance, Tumor note: Copyright © 2017. This manuscript version is published under a Creative Commons Attribution Non-commercial Non-derivative 4.0 International licence (CC BY-NC-ND 4.0). This licence allows you to share, copy, distribute and transmit the work for personal and non-commercial use providing author and publisher attribution is clearly stated. Further details about CC BY licences are available at http://creativecommons.org/licenses/by/4.0. Access may be initially restricted by the publisher. abstract: Gene-silencing miRNA and siRNA are emerging as attractive therapeutics with potential to suppress any genes, which could be especially useful in combination cancer therapy to overcome multidrug resistant (MDR) cancer. Nanomedicine aims to advance cancer treatment through functional nanocarriers that delivers one or more therapeutics to cancer tissue and cells with minimal off-target effects and suitable release kinetics and dosages. Although much effort has gone into developing circulating nanocarriers with targeting functionality for systemic administration, another alternative and straightforward approach is to utilize formulations to be administered directly to the site of action, such as pulmonary and intratumoral delivery. The combination of gene-silencing RNA with drugs in nanocarriers for localized delivery is emerging with promising results. In this review, the current progress and strategies for local co-administration of RNA and drug for synergistic effects and future potential in cancer treatment are presented and discussed. Key advances in RNA-drug anticancer synergy and localized delivery systems were combined with a review of the available literature on local co-administration of RNA and drug for cancer treatment. It is concluded that advanced delivery systems for local administration of gene-silencing RNA and drug hold potential in treatment of cancer, depending on indication. In particular, there are promising developments using pulmonary delivery and intratumoral delivery in murine models, but further research should be conducted on other local administration strategies, designs that achieve effective intracellular delivery and maximize synergy and feasibility for clinical use. date: 2017-03-16 date_type: published official_url: http://doi.org/10.1016/j.ctrv.2017.03.004 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1286374 doi: 10.1016/j.ctrv.2017.03.004 pii: S0305-7372(17)30041-5 lyricists_name: Larsson, Lars lyricists_id: LMLAR62 actors_name: Larsson, Lars actors_name: Williamson, Brooke Leigh actors_id: LMLAR62 actors_id: BLHAR98 actors_role: owner actors_role: impersonator full_text_status: public publication: Cancer Treatment Reviews volume: 55 pagerange: 128-135 event_location: Netherlands issn: 1532-1967 citation: Larsson, M; Huang, W-T; Liu, D-M; Losic, D; (2017) Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential. Cancer Treatment Reviews , 55 pp. 128-135. 10.1016/j.ctrv.2017.03.004 <https://doi.org/10.1016/j.ctrv.2017.03.004>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/1549825/1/Local%20co-administration%20of%20gene-silencing%20RNA%20and%20drugs%20in%20cancer%20therapy%20State-of-the%20art%20and%20therapeutic%20potential_Post%20print%20%28002%29.pdf